|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that GAS5 functioned as a tumor suppressor role in HCC through regulation of miR-21-PTEN singling pathways, suggesting a potential application of GAS5 in HCC therapy.
|
31705194 |
2020 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA hypomethylation might play an important role in elevated GAS5 transcription in HCC.© 2018 BioFactors, 45(2):244-252, 2019.
|
30537372 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Taken together, our study revealed the important roles of GAS5/miR-1323/TP53INP1 axis in HCC progression.
|
31190897 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, GAS5 functioned as a tumor suppressor in HCC metastasis through directly interacting with miR-182 and abrogating its oncogenic function in this setting.
|
30755815 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of plasmatic circulating miR-126-3p and GAS5 were significantly higher and lower in HCC patients compared to healthy subjects, respectively.
|
31235746 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functionally, GAS5 suppresses while miR-135b promotes HCC cell invasion capacities <i>in vitro</i>.
|
30733959 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistent to the computationally predicted miRNA-lncRNA interaction, negative correlations were observed between levels of GAS5 and miR-34a in RCC samples (r = -0.949, p < 0.001), GB (r = -0.518, p < 0.001) and HCC (r = -0.455, p = 0.013).
|
30289954 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that the anti-HCC mechanism of corylin's action lies in the upregulation of tumor suppressor long noncoding RNA growth arrest-specific transcript 5 (GAS5) and the activation of its downstream anticancer pathways.
|
29382035 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies showed that genetic variant rs145204276 in the promoter region of GAS5 was associated with the development of human cancer including colorectal cancer and hepatocellular cancer.
|
30013899 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In current study, we investigated the possible association between susceptibility of lung cancer and GAS5 rs145204276, which showed contradictory roles in carcinogenesis of colorectal cancer and hepatocellular carcinoma.
|
29207621 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of GAS5 correlated with poor recurrence-free survival (RFS) in hepatocellular carcinoma (HR = 2.40, 95%CI: 1.27-4.54, <i>P</i> = 0.007), and was associated with lymph node metastasis (OR = 1.92, 95% CI: 1.44-2.57, <i>P</i> < 0.001), distant metastasis (OR = 2.7, 95% CI: 1.05-6.97, <i>P</i> = 0.040), poor clinical stage (OR = 0.26, 95% CI: 0.18-0.38, <i>P</i> < 0.001), larger tumor size (OR = 3.21, 95% CI: 2.08-4.95, <i>P</i> < 0.001), and poor tumor differentiation (OR = 1.98, 95% CI: 1.40-2.80, <i>P</i> < 0.001).
|
29029523 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative polymerase chain reaction and in situ hybridization were performed to investigate the expression of GAS5 in tumor tissues and corresponding adjacent tissues from 50 patients with HCC.
|
26707238 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Then, overexpression of GAS5 suppresses the migration and invasion of HCC cells and high expression of miR-21 largely eliminates GAS5-mediated suppression of HCC cell migration and invasion.
|
26404135 |
2016 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma.
|
26163879 |
2015 |